Healthcare Industry News: Ablatherm
News Release - December 13, 2006
EDAP Strengthens UK, German Sales Teams; Proven Senior Professionals Added in Growth MarketsLYON, France, Dec. 13 (HSMN NewsFeed) -- EDAP TMS S.A. (Nasdaq: EDAP ), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, reports the appointment of Mark Perry as Senior Sales Director in charge of the United Kingdom. Additionally, the company has added two senior sales personnel in its growing German market operations.
EDAP Chief Operating Officer Marc Oczachowski stated, "EDAP committed that it would add key staff in growing markets at appropriate times, with these new additions now promoting Ablatherm-HIFU as a well documented and effective source of treatment in top growth regions. We are very excited to bring on board highly regarded, experienced and proven senior professionals strengthening our already aggressive sales teams. They will be fully focused on expanding HIFU in growing European markets and helping us reach our targets including an increased focus on the United Kingdom now that EDAP is well established with local thought leaders and generating increased interest for adding Ablatherm-HIFU therapy to the treatment options being offered at clinical sites in that country. These additions directly reflect the ongoing progress we see in growing demand for HIFU therapy and our need for additional sales staff to meet this demand."
In his new role, Perry will be in charge of developing HIFU activity in the UK, in line with the Company's strong focus on expanding its RPP business model in key European countries where HIFU growth is expected. Perry joins EDAP from Bausch & Lomb where he served as Regional Manager. He previously served in marketing and sales roles at Chiron Vision Europe and Laboratories Domilens.
The company has also added Uwe Perkuhn as Senior Sales Manager for Northern Germany effective December 1, 2006. Perkuhn has 18 successful years of sales experience in medical technology, primarily in ultrasound and therapeutic urology devices including lasers and lithotripsy. He is already familiar with HIFU and the Ablatherm device through prior work with EDAP on a consulting basis.
Ludwig Frank will join on January 1, 2007 as a Senior Sales Manager for Southern Germany and German speaking sites in Switzerland. Frank brings 26 successful years of experience in medical devices sales, primarily in ultrasound, lasers, lithotripsy and x-ray technologies. Frank recently played a leading role in launching and successfully establishing GreenLight® laser in Germany. He developed networks and built recognition with key leaders in the Urology Community.
Ludwig and Perkuhn both have worked many years with Dornier Med Tech, the worldwide leader in lithotripsy. They today bring to EDAP their wealth of experience in dealing with key accounts in the urology field and a large network built over years of experience in the marketplace.
"With their long experience and excellent urologic contacts in these regions, we are very confident that we continue to build the best team to bring HIFU to a broader geographic audience in these important areas," said Judith Johannsen, general manager of EDAP GmbH. "EDAP is already the leading provider in Germany with growing interest in Ablatherm-HIFU based on the increasing recognition of HIFU success. We believe we have the right structures and people on board to reach aggressive 2007 targets, especially in terms of the RPP business in the German market."
About EDAP TMS S.A.
EDAP TMS S.A. develops and markets Ablatherm, the most advanced and clinically proven choice for High Intensity Focused Ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. The company is also developing this technology for the potential treatment of certain other types of tumors. EDAP TMS S.A. also produces and commercializes medical equipment for treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL).
For more information on the Company, contact Halliburton Investor Relations at (972) 458-8000, the Corporate Investor Relations Dept at +33 (0)4 78 26 40 46 or see the Company's Web sites at http://www.edap-tms.com and http://www.hifu-planet.com .
In addition to historical information, this press release contains forward-looking statements that involve risks and uncertainties. These include statements regarding the Company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in these forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission. Ablatherm- HIFU treatment is in clinical trials but not yet FDA approved or marketed in the United States.
Source: EDAP TMS
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.